Arrhythmias – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Arrhythmias – Drugs In Development, 2024 report and make more profitable business decisions.
An arrhythmia is a problem with the rate or rhythm of the heartbeat. During an arrhythmia, the heart can beat too fast, too slow, or with an irregular rhythm. Signs and symptoms include anxiety, weakness, dizziness, and light-headedness; fainting or nearly fainting; sweating; shortness of breath; and chest pain. Treatment includes anti-arrhythmics and anticoagulants.
The Arrhythmias drugs in development market research report provide comprehensive information on the therapeutics under development for Arrhythmias, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Arrhythmias and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Arrhythmias | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 27 molecules, with 18 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Arrhythmias therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Arrhythmias pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Arrhythmias treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Academic Pharmaceuticals IncARMGO Pharma Inc
BioMarin Pharmaceutical Inc
Cardurion Pharmaceuticals LLC
Cynata Therapeutics Ltd
Espero BioPharma Inc
Fuso Pharmaceutical Industries Ltd
Galectin Therapeutics Inc
Gilead Sciences Inc
Jiangsu Kanion Pharmaceutical Co Ltd
Les Laboratoires Servier SAS
Mayo Clinic
Nissan Chemical Corp
Oregon Health & Science University
Orion Corp
SignPath Pharma Inc
Stablix Inc
Tel Aviv University
Thryv Therapeutics Inc
University of California Los Angeles
University of Florence
University of Gottingen
University of Illinois
University of Iowa
University of Sydney
Vasa Therapeutics SP Zoo
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Arrhythmias reports